
Retatrutide is the next step beyond Semaglutide and Tirzepatide — it pulls three metabolic levers instead of one or two. The added glucagon action is thought to turn up the body's own calorie burn while still reducing appetite.
A deeper look for the curious
For readers who want the full mechanism — feel free to skim.
Retatrutide is the first peptide to activate three metabolic hormone signals at once — GLP-1, GIP, and glucagon. The added glucagon signal actually turns up the body's own calorie burn, while the other two reduce appetite and improve blood sugar. Three levers instead of one or two — which is why early trials show the largest weight reductions yet.
What researchers have observed in studies
First-ever triple incretin receptor agonist
Activates glucagon-mediated hepatic fat oxidation
Enhances energy expenditure through thermogenesis
Demonstrates effects across all three metabolic pathways
GLP-1 + GIP + Glucagon receptors (triple agonist)
39 amino acid peptide
Amino acid chain
What scientists study this compound for
Phase 2 clinical data has shown the largest reductions in body weight of any metabolic peptide studied to date — in the range of 24% over 48 weeks.
Researched for actively burning fat out of the liver through the glucagon receptor pathway.
Studied for aggressive improvements in glucose control and insulin sensitivity.
Early data suggests it may increase resting calorie burn, not just reduce appetite.
High-performance liquid chromatography confirms compound purity for every batch we produce.
ESI-MS verifies molecular weight and structural identity match the target compound.
Complete analytical data including chromatograms and mass spectra available per batch.
Laboratory use only. This product is sold for laboratory use and is not intended for human consumption or medical use.
Third-party verified. Typical purity ≥97%.